Darwin AG will participate in two capital markets conferences in spring 2026, presenting to different investor audiences and providing updates on its financial performance and strategic direction in the personalized healthcare sector. The company's participation highlights the growing financial and market interest in precision health solutions and provides critical transparency for stakeholders evaluating the sector's investment potential.
The company will first attend the Invest conference in Stuttgart from April 17 to 18, 2026, at Messe Stuttgart. This event targets retail investors and covers various investment topics. Under the theme "Invest in the Future of Precision Health," CEO Dr. Daniel Wallerstorfer will present the company's equity story on April 17 at 5:30 p.m., offering insights into how personalized solutions are shaping the healthcare market. Interested visitors can meet management at Hall 4, Booth 4E32. Further information about Invest can be found at https://www.invest-messe.de.
Subsequently, Darwin AG will present at the Equity Forum's 2026 Spring Conference, a MiFID II-compliant professional event for institutional investors, analysts, and financial journalists, held from May 11 to 12 at the Flemings Selection Hotel in Frankfurt. The company will provide a corporate update, present audited financial results for 2025, and share its operational and strategic outlook. The 2025 consolidated financial statements will be published in the Annual Report on May 12, 2026.
The presentation at the Equity Forum is scheduled for May 12 from 9:20 a.m. to 9:55 a.m., after which Dr. Wallerstorfer will be available for one-on-one meetings that can be scheduled via the conference website's event tool. More information about the 2026 German Spring Conference can be found at https://www.equityforum.de.
This dual-conference approach is significant as it demonstrates Darwin AG's commitment to engaging with both retail and institutional investment communities during a period of increased focus on personalized medicine. The presentations and financial disclosures will provide investors with essential data to assess the company's performance in the competitive healthcare genetics market. The release of 2025 audited results alongside strategic updates offers a comprehensive view of the company's financial health and future direction, which is crucial for investment decisions in the rapidly evolving precision health industry.
The company's focus on personalized products based on genetic analysis for disease diagnosis, treatment, and prevention, along with investments in biotech and life sciences, positions it within a high-growth sector. These conferences serve as important platforms for communicating how genetic analysis technologies translate into market opportunities and financial results, influencing both capital allocation and industry trends in European healthcare.
